beta-alanine has been researched along with Blood Loss, Surgical in 9 studies
Blood Loss, Surgical: Loss of blood during a surgical procedure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required." | 9.16 | Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. ( Avezum, A; Connolly, SJ; Douketis, J; Eikelboom, J; Ezekowitz, M; Healey, JS; Heidbuchel, H; Heidbuchle, H; Oldgren, J; Reilly, P; Themeles, E; Wallentin, L; Yang, S; Yusuf, S, 2012) |
| "Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required." | 5.16 | Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. ( Avezum, A; Connolly, SJ; Douketis, J; Eikelboom, J; Ezekowitz, M; Healey, JS; Heidbuchel, H; Heidbuchle, H; Oldgren, J; Reilly, P; Themeles, E; Wallentin, L; Yang, S; Yusuf, S, 2012) |
| " We review new anticoagulants that have been introduced recently to the market or that are undergoing investigations for treatment of nonvalvular atrial fibrillation and venous thromboembolism prophylaxis: Dabigatran, rivaroxaban, apixiban, and edoxaban." | 4.89 | The novel anticoagulants: the surgeons' prospective. ( Martin, EN; Money, SR; Shamoun, FE, 2013) |
| "Prospective, double-blind studies in orthopaedic patients have been conducted using the direct thrombin inhibitor dabigatran etexilate (hereafter referred to as dabigatran), with two doses investigated and approved for adults (220 mg and 150 mg once daily) to prevent venous thromboembolism (VTE)." | 4.88 | Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected]. ( Clemens, A; Dahl, OE; Eriksson, BI; Kurth, AA; Noack, H; Rosencher, N, 2012) |
| "To reverse the anticoagulant effects of warfarin in patients who are bleeding or need surgery, exogenous vitamin K (phytonadione) may be used in combination with another, shorter-acting intervention, such as fresh frozen plasma (FFP), prothrombin complex concentrate (PCC), recombinant factor VIIa, or activated PCC (aPCC)." | 3.79 | Pharmacologic interventions for reversing the effects of oral anticoagulants. ( Kalus, JS, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Llau, JV | 1 |
| Ferrandis, R | 1 |
| Castillo, J | 1 |
| de Andrés, J | 1 |
| Gomar, C | 1 |
| Gómez-Luque, A | 1 |
| Hidalgo, F | 1 |
| Torres, LM | 1 |
| McKenzie, JL | 1 |
| Douglas, G | 1 |
| Bazargan, A | 1 |
| Kalus, JS | 1 |
| John, A | 1 |
| Michel, MS | 1 |
| Tran, H | 1 |
| Joseph, J | 1 |
| Young, L | 1 |
| McRae, S | 1 |
| Curnow, J | 1 |
| Nandurkar, H | 1 |
| Wood, P | 1 |
| McLintock, C | 1 |
| Dahl, OE | 1 |
| Kurth, AA | 1 |
| Rosencher, N | 1 |
| Noack, H | 1 |
| Clemens, A | 1 |
| Eriksson, BI | 1 |
| Healey, JS | 1 |
| Eikelboom, J | 1 |
| Douketis, J | 1 |
| Wallentin, L | 1 |
| Oldgren, J | 1 |
| Yang, S | 1 |
| Themeles, E | 1 |
| Heidbuchel, H | 1 |
| Heidbuchle, H | 1 |
| Avezum, A | 1 |
| Reilly, P | 1 |
| Connolly, SJ | 1 |
| Yusuf, S | 1 |
| Ezekowitz, M | 1 |
| Turpie, AG | 1 |
| Kreutz, R | 1 |
| Llau, J | 1 |
| Norrving, B | 1 |
| Haas, S | 1 |
| Shamoun, FE | 1 |
| Martin, EN | 1 |
| Money, SR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Observational Study of the Direct Oral Anticoagulants Periprocedural Management[NCT03182218] | 1,100 participants (Actual) | Observational | 2015-02-28 | Completed | |||
| Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants[NCT02185027] | 1,166 participants (Actual) | Observational | 2013-06-30 | Completed | |||
| Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atria[NCT00262600] | Phase 3 | 18,113 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Prospective Study of the Assessment of the Dental Protocol for Tooth Extraction in Patients With Atrial Fibrillation in Continuous Use of New Oral Anticoagulants: A Pilot Study[NCT03181386] | Phase 3 | 60 participants (Actual) | Interventional | 2017-05-03 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST>3xULN and total bilirubin > 2 x ULN (NCT00262600)
Timeframe: 36 months
| Intervention | participants (Number) |
|---|---|
| Dabigatran 110 mg | 11 |
| Dabigatran 150 mg | 14 |
| Warfarin | 21 |
Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 1.54 |
| Dabigatran 150 mg | 1.11 |
| Warfarin | 1.71 |
Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 4.85 |
| Dabigatran 150 mg | 4.32 |
| Warfarin | 5.20 |
Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 4.26 |
| Dabigatran 150 mg | 3.68 |
| Warfarin | 4.35 |
"Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25~Major bleeds are adjudicated, whereas minor bleeds are investigator reported." (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) | |
|---|---|---|
| Major bleeds | Minor bleeds | |
| Dabigatran 110 mg | 2.99 | 13.16 |
| Dabigatran 150 mg | 3.55 | 14.85 |
| Warfarin | 3.81 | 16.37 |
Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH) (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage)] (Number) | |
|---|---|---|
| intracerebral hemorrhage | intracranial hemorrhage (ICH) | |
| Dabigatran 110 mg | 0.12 | 0.23 |
| Dabigatran 150 mg | 0.10 | 0.32 |
| Warfarin | 0.38 | 0.76 |
5 reviews available for beta-alanine and Blood Loss, Surgical
| Article | Year |
|---|---|
[Recommendations on use of direct oral anticoagulants in the perioperative period].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Dabigatran | 2012 |
Perioperative management of anticoagulation in elective surgery.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Cardiovascular Di | 2013 |
Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected].
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; | 2012 |
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation | 2012 |
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation | 2012 |
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation | 2012 |
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation | 2012 |
The novel anticoagulants: the surgeons' prospective.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Tr | 2013 |
1 trial available for beta-alanine and Blood Loss, Surgical
3 other studies available for beta-alanine and Blood Loss, Surgical
| Article | Year |
|---|---|
Pharmacologic interventions for reversing the effects of oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-A | 2013 |
[Rivaroxaban, dabigatran and apixaban: new anticoagulants in operative urology].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Dabigatran | 2014 |
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagu | 2014 |